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Abstract
Many studies have shown that change in metabolism caused by diabetes can influence the bone metabolism in a
way that quality and strength of bone is decreased. A 6 times and 2 times increased risk of fracture is reported in
patients with type 1 and type 2 diabetes, respectively. There are several mechanisms by which diabetes can affect
the bone. The fact that some of these mechanisms are acting in opposite ways opens the door for debate on
pathways by which diabetes affects the bones. On the other hand, bone is not a simple organ that only get
influence from other organs, but it is an endocrine organ that by secreting the agents such as osteocalcin,
adiponectin and visfatin which can affect the insulin sensitivity and metabolism. In this paper we tried to briefly
assess the latest finding in this matter.
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Background
Osteoporosis is a common skeletal system disease char-
acterized by bone density attenuation and normal bone
microstructure deterioration. All these changes can lead
to an increased risk of fracture [1]. Many of these frac-
tures are related to increased morbidity and mortality
seen in these patients. It has been shown in recent years
that diabetes, as a common disease with an increasing
prevalence, is associated with increased morbidity and
mortality. Moreover, recent data has revealed that both
type 1 and 2 diabetes are associated with an increased
risk of osteoporosis related fractures [2]. Diabetes-
induced changes in metabolism significantly affect the
bone metabolism and increase the risk of fracture by six
times in type 1 and by 2 times in type 2 diabetic patients
[3]. Although many studies have shown the negative ef-
fects of diabetes on the bone quality and strength, the
debate is still open [4, 5].
Part of this discrepancy can be attributed to the mecha-
nisms involved. There are several mechanisms by which
diabetes can affect the bone (Table 1). Some of these mech-
anisms act in opposite directions. In this paper we tried to
briefly review the mechanisms.
Main text
1. Hyperglycemia - Hyperglycemia can attenuate the
bone density through several mechanisms.
1.1. Toxic effects caused by high levels of glucose
could directly reduce the osteoblast function
and number [6].
1.2. High levels of glucose could independently
change the levels of osteoblast gene expression
through the osmotic and non-osmotic pathways
[7]. These changes result in inhibition of osteo-
blast maturation and bone mineralization.
1.3. Impairment of osteoblast maturation, caused by
high glucose levels, results in an impaired
response to 1, 25 hydroxy vitamin D3 (1,
25(OH)-D3). This indirectly causes the down
regulation of vitamin D receptors.
1.4. Production of glycation end products: High
glucose levels, through non-enzymatic pathways,
may induce glycation of various proteins and
produce the products called advanced
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glycosylation end-products (AGEs). These
products are seen in different tissues of diabetic
subjects and are supposed to be involved in
pathogenesis of diabetes [8]. It seems hypergly-
cemia and AGEs have a major role in fragility of
bones in both type of diabetes [9]. In cortical
bone, accumulation of AGEs causes an increase
in production of cross-links between collagens.
Although this process can increases the rigidity
and hardness of collagen, it does not affect the
bone mineralization. In fact there is a negative
relation between AGEs and size and fragility of
the human trabecular bone [10] which could
explain the increased bone fragility and fracture
in diabetic subjects. Moreover, apart from the
direct effects of high glucose, accumulation of
AGEs has a direct inhibitory effect on the
proliferation and differentiation of bone cells.
1.5. Oxidative stress: production and accumulation
of AGEs can induce the cellular apoptosis
through production of reactive oxygen species
(ROS) and oxidative stress [11].
1.6. High levels of glucose causes an increase in
differentiation of bone marrow mesenchymal
cells into adipocytes, which in turn could
rise the adipogenesis and attenuate the
osteogenesis [12].
2. Insulin, insulin like growth factor-1 (IGF-1) and
other growth factors
2.1. Apart from IGF-1, insulin has some osteogenic
effects [13], and directly and indirectly induces
the production and differentiation of osteoblasts
[14–16]. The direct effect is mediated through
insulin and IGF-1 receptors located on osteo-
blast. For example it has been shown that in
response to exogenous insulin, the osteoblasts
cultured cells increase collagen production
[17]. The indirect effect of insulin is mediated
through both the control of blood glucose levels
and its effects on parathyroid hormone (PTH),
IGF-1 and vitamin D [18–20]. In animal models
of type 1 diabetes(T1DM), reduced bone density
and osteoporosis has been reported [21, 22].
Moreover in clinical studies, it has been shown
that bone mineral density(BMD) of femoral
neck in T1DM subjects is lower than type 2
diabetes (T2DM) patients [23]. This finding is
explained with lack of insulin in T1DM patients
and could account for higher risk of osteopenia
and osteoporosis in young age T1DMs [24].
Nevertheless higher BMD levels which have
been reported in patients with T2DM in
comparison with patients with T1DM could
be explained by higher body weight levels and
BMD in the T2DM patients [25].
2.2. The insulin analogue, IGF-1, can affect the bone
metabolism. In fact IGF-1 is regarded as a key
regulator of bone metabolism that increases
both the bone deposition in matrix and osteo-
blasts recruitment and decreases the bone loss
and collagen destruction in the bone [26]. In
spontaneously diabetic BB rats, the osteoblasts
number is normal, however there is an impair-
ment in bone mineralization which is similar to
what is seen in osteomalacia (osteomalacia-like
mineralization defect) [27]. Moreover, use of
controlled release of IFG-1 as a drug model rep-
resented a promising results for bone defects
that do not heal under normal therapeutic con-
ditions [28]. In clinical studies, an association
between vertebral fractures and decreased levels
of IGF-1, has been reported in postmenopausal
Table 1 Summary of main mechanisms by which diabetes
affect bone
1- Hyperglycemia • Differentiation of MSCs to fat cells↑,
osteoblast function and number↓,
osteoblast gene expression↓, osteoblast
maturation↓
• AGEs↑, Oxidative stress↑, Adipogenesis↑
2- Insulin, IGF-1 Insulin has osteogenesis effects:
• directly: osteoblast function and number↑,
osteoblast maturation↑
• Indirectly: control of blood glucose levels,
IGF-1, PTH,and vitamin D
3- Calcium, vitamin D and
calciotrophic hormones
• Calcium loss (kidney and bones) ↑
• vitamin D deficiency (genetic
polymorphisms)↑
• PTH ↓
4- Diabetic bone marrow
adiposity
Osteopenic adiposity:
• Differentiation of MSCs to fat cells↑
• Stimulate adipogenesis through PPARγ↑
• Inhibition of osteoblast profanation by
FFAs
5- Secretion of bone
marrow cells
• Adiponectin: ↑ inT1DM (micro vascular
complications), ↑↓in T2DM
• Leptin: ↓ inT1DM,↑in T2DM
• Osteocalcin↓
6- inflammation • Systemic inflammation (chronic)
• Bone inflammation: inflammatory cells &
mediators ↑, markers of osteoblast
inhibition↑
7- Vasculopathy • vascular supply to bone↓
• Fragility fracture risk↑
8- Antidiabetic agents • positive effects on bone metabolism:
Insulin, Metformin, Sulfonylurea, DPP-4 In-
hibitors (Sitagliptin)
• negative effects on bone metabolism: TZDs
AGEs Advanced Glycosylation End-Products, IGF-1 Insulin, Insulin-like growth
factor-1,PTH parathyroid hormone, PPARγ peroxisome proliferator-activated
receptor γ, FFAs free fatty acids, DPP-4 Dipeptidyl peptidase-4,
TZDs thiazolidinediones
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T2 diabetic women [15, 29]. The IGF-1 and 17-
β-estradiol can be considered as the most signifi-
cant hormonal determinants of the BMD of the
hip and femoral neck in young men, however,
the correlation do not remain significant for
IGF-1 in men aged over 60 years [30]. On the
other hand, IGF-1 levels are lower in patients
with T1DM than patients with T2DM [31]. And
last but not least, according to cross-sectional
trials evaluated the association between bone
turnover markers (BTMs) and fracture, IGF-1
might be considered as a predictor of fracture
risk in diabetes [32]. Further investigations are
highly recommended in order to provide
comprehensive knowledge about related
mechanisms.
3. Calcium, vitamin D and calciotrophic hormones
Calcium and its metabolism have a fundamental role
in bone metabolism. Therefore any change that affects
the equilibrium between systemic factors balancing the
calcium levels can result in bone loss [33]. The simultan-
eous presence of vitamin D deficiency and diabetes
(either type1 or 2), sharply increases the incidence of
osteopenia and osteoporosis [21, 34, 35]. The PTH also
has some moderating effects on osteoblasts and any im-
balance in its concentration could result in bone loss
and increased risk of fracture [36, 37].
3.1. Calcium-Mechanisms by which diabetes can affect
the calcium metabolism are complicated, however
in most parts they are related to calcium loss
through kidney [38]. In diabetic rats, the kidney
secretion of calcium is higher than non-diabetic
rats. In addition the levels of 1,25(OH)2-D3 and
vitamin D binding protein is almost ten times lower
than normal group [21]. In diabetic mice there is
an association between amount of calcium secreted
in urine and decreased bone density [33]. The
Quantified-PCR in the kidney showed changes in
mRNA expression levels of 25-hydroxyvitamin D-
24-hydroxylase (down regulation)and 25-
hydroxyvitamin D-1α- hydroxylase(up regulation)
as well as down regulation of calcium transferring
receptors mRNA, plasma membrane Ca-ATPase
and vitamin D receptors (VDR) genes [33].
3.2. Vitamin D- In the first two years of life, the
vitamin D deficiency causes Rickets, while in adults
vitamin D deficiency can induce or exacerbate
osteoporosis or cause osteomalacia [39]. It has been
shown that vitamin D has a role in pathogenesis of
both types of diabetes [40]. In T1DM, it seems that
vitamin D produces its effects through affecting the
immune system, while in T2DM the ameliorating
effects of vitamin D on B cell function and also
increased insulin sensitivity is more prominent
[41]. Moreover, T1DM might be associated to some
genetic polymorphisms linked to vitamin D
deficiency [42]. An association between vitamin D
deficiency and diabetes incidence, management,
complications, and mortality has been reported
[43–45]. Although many studies indicate that
vitamin D deficiency could be a risk factor for
both types of diabetes [41, 46], there is still
debate about whether vitamin D deficiency is a
consequence of diabetes or a predisposing factor
[47]. There are no randomized clinical trials
investigate the effect of vitamin D supplementation
on the incidence of diabetes.
3.3. PTH- Animal studies have shown that serum
levels of PTH, vitamin D, calcium, Mg and
Phosphate are lower in diabetic models than
controls [48]. Moreover, in diabetic mice treatment
with PTH-related protein, protein mostly produced
by mature osteoblasts, can stop and even reverse
the trabecular bone loss. This finding can indicate
the modulatory and stimulatory effects of PTH on
osteoblast function and maturation [36, 49, 50].
It has been shown that increased levels of PTH are as-
sociated with insulin resistance [51]. Moreover, there is
an association between decreased levels of PTH and ver-
tebral fracture in T2 diabetic patients [52], which could
be related to attenuated anabolic effects of PTH on
bones [37]. In young insulin-requiring diabetic patients
serum levels of 1,25-(OH)2 vitamin D3 was decreased
but PTH, calcium and Phosphate levels remained in nor-
mal range, probably with the cost of decreased cortical
bone in these patients [35]. The anabolic effect of inter-
mittent administration of PTH and its synthetic peptide
fragment, teriparatide (PTH 1-34, TPTD) on bone has
been well documented [53]. Increased serum levels of
osteocalcin after PTH therapy may describe the anabolic
mode of action [50].
There are trials demonstrated the bone healing effect
of PTH and, a small number of case reports illustrated a
potential role for TPTD to improve healing of nonunion
and stress fractures in patients with diabetes [54, 55].
Moreover, the beneficial effects of PTH on osteoporosis
caused by thiazolidinediones (TZDs) could be an inter-
esting subject to be assessed by researchers [56].
4. Diabetic bone marrow adiposity
Recently, obesity is regarded as an inflammatory state
that could result in metabolic disturbance [57]. The adi-
pokines including leptin, adiponectin, visfatin and resis-
tin have a role in insulin resistance in obese subjects and
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there is a significant relation between insulin resistance
and obesity [57]. Bone fat has an important role in path-
ology of bone loss. Even recently a new term, osteopenic
obesity, has been introduced that point out to effects of
fat tissue on bone metabolism [58].
There are several animal studies in which a higher fat
content in the bone marrow of diabetic subjects compared
to their healthy counterparts are observed [49, 59, 60].
Adipocytes and osteoblasts have a common source, both
originating from pluripotent mesenchymal stem cells
(MSCs). MSCs can differentiate into these two cell lines;
however the factors that affect this differentiation can also
have effects on bone density. Adipocytes produce free
fatty acids whose lipotoxic effects can directly inhibit the
osteoblast proliferation [61, 62]. These fatty acids can re-
sult in an increased insulin resistance [63, 64].
To date, some of the factors affecting the differentiation
of bone marrow cells have been known. For example the
transcription factors runt-related transcription factor 2
(Runx2) stimulates the osteogenesis and peroxisome
proliferator-activated receptor γ (PPARγ) stimulates the ad-
ipogenesis [65]. Hyperglycemia can stimulate the differenti-
ation of MSCs to fat cells [66–68]. For example in tibia of
type 1 diabetic rats, the expression of PPARγ as well as the
number of fat cells is increased when compared to control
[64]. BMD and trabecular volume is also increased in
mouse with birth defect in PPARγ [69]. Some anti-diabetic
medications may induce osteopenia with same mechanism.
For example in mice, rosiglitazone therapy, as the agonist
of PPARγ [65], can result in a massive bone loss as well as
increase in the fat content of bone [69]. However it cannot
cover for all the osteopathies seen in diabetes. In diabetic
rats, therapy with antagonists of PPARγ decreases the fat
content of bone marrow; however it cannot inhibit the
bone loss and attenuation of BMD. This observation indi-
cates that only part of bone loss seen in diabetes is related
to PPARγ mechanism and there is still so many areas in
this matter that needs to be assessed [59].
5. Secretion of bone marrow cells
5.1. Adipocyte-derived hormones- Adiponectin,
Leptin, Resistin
In-vitro as well as animal studies is has been shown
that adipose-derived hormones (such as adiponectin,
leptin, visfatin, and resistin) have role in bone metabol-
ism [70], however their complete mechanism of action is
not clear. Therefore, it is not reasonable to employ the
adiponectin as a bone health assessment factor [71].
5.1.1. Adiponectin
Adiponectin is a hormone secreted by fat tissue with
anti -inflammatory effects. This hormone can increase the
insulin sensitivity and also regulates the energy hemostasis
[72]. Their receptors are located on osteoblast which
might indicate the role of this hormone in fat and bone
metabolism [73]. Its effects are not clearly understood, al-
though some of its known actions on bone metabolism
seem to be opposite. For example in adiponectin knock
out rats, a decrease in trabecular bone and an increase in
bone marrow fat are observed. Beside, adiponectin treat-
ment in these rats decreases the osteoclast number and
increases the trabecular bone. While this treatment can
increase the conversion of stromal cell of bone to osteo-
blasts [74], at the same time can activate the receptor acti-
vator of nuclear factor kappa-b ligand (RANKL) which
has negative effects on bone metabolism [51].
In clinical studies an inverse relation between adipo-
nectin levels and BMD is observed, which is less prom-
inent in obese subjects and increases with weight loss
[75]. Women has higher levels of serum adiponectin
compared to men [75]. There is also some evidence that
indicate the increased insulin sensitivity caused by adi-
ponectin is limited to female subjects [76, 77]. Further-
more, it has been shown that increased levels of
adiponectin and not leptin, can independently increase
the risk of fractures [70]. The altered levels of adiponec-
tin is reported in various disease [75]. In osteoarthritis
the adiponectin secretion is decreased [75]. in obese
subjects the low serum levels of adiponectin showed an
association with T2 DM, metabolic syndrome, athero-
sclerosis and cardiovascular disease [78]. Although the
decreased levels of adiponectin in T2 diabetic subjects
are associated with increased risk of cardiovascular
disease [57], the levels of adiponectin are increased in
T1 diabetic patients who suffer from micro vascular
complications [79]. However it is not clear that this in-
crease reflects the pathological role of adiponectin in
microvascular complications of diabetes or is a beneficial
response due to counter-regulatory effects. Investigating
the association between this hormone and various dis-
eases, another potential affecting factor, except gender,
which worth to be considered is BMI. This could lead to
obtain a better understanding of the relationships be-
tween variables and also using these relationships in the
process of predicting the occurrence of diseases.
Either way full understanding of adiponectin relevant
interventions not only can be useful in understanding
the mechanisms of diabetic osteopathy but also might
help discover the new therapies for diseases such as
diabetes, metabolic syndrome, cardiovascular disease,
and obesity.
5.1.2. Leptin
Leptin has a regulatory role in bone metabolism. This
protein by affecting the stromal cell of bone marrow
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inhibits the differentiation toward osteoclast and stimu-
lates the osteoblast production [80–82]. In T1 diabetic
mice, leptin levels is significantly low with increased
bone marrow fat and decrease bone mass [80]. Adminis-
tration of leptin to leptin-deficient ob/ob non- diabetic
fatty mice deceases the fat content of bone and increase
the bone mass [83]. On the other hand, administration
of leptin to T1 diabetic mice decreases the bone fat,
however it cannot inhibit the bone loss caused by dia-
betes [83]. In clinical studies, the results are conflicting.
T1 diabetic subjects are presented with elevated [84] or
very little attenuated levels of leptin [85]. The dissimilar-
ities might be contributed to low BMI in this group of
patients (T1DM). In T2 diabetic subjects BMI is usually
higher and therefore the serum concentration of leptin
is increased. However, it has been proven that leptin
levels, independently of BMI, has a positive association
with BMD [86]. In diabetic Hispanics individuals, a sig-
nificant inverse relationship has been shown between
serum leptin and BMD as well [87]. Similar to adiponec-
tin and IGF-1, it seems understanding the mechanisms
by which leptin produces its effects on bone and fat tis-
sues can lead to development of new therapeutic strat-
egies in the treatment of various diseases.
5.1.3. Visfatin and resistin
Similar to adiponectin, visfatin can increase the insulin
sensitivity [57]. The visfatin, highly expressed by cells of
bone marrow, produces its effects on bone metabolism
through affecting the osteoblasts; increasing the glucose ab-
sorption and mRNA levels of osteogenic factors [88]. Visfa-
tin levels are higher in obese subjects [57]. A meta-analysis
showed that visfatin can be used for prediction of risk of in-
sulin resistance, diabetes, and metabolic syndrome [89].
In contrast to visfatin that has insulin-like effects,
resistin has anti-insulin effects, an effect that stands for
its name (resistin for resistance to insulin). Anti-diabetic
agents such as pioglitazone can decrease its concentra-
tion in serum [63]. In leptin knock out ob/ob obese
mice, increased levels of resistin are observed which in-
dicate the association between resistin and leptin [90].
5.2. Osteoblast derived hormones: Osteocalcin
Osteocalcin (OC), as the major protein secreted by
osteoblasts, is involved in glucose metabolism. OC me-
diates the insulin secretion from pancreas and also has
a positive effect on adiponectin secretion from fat cells
[91]. OC even in a very low concentration (at picomolar
range) can be sufficient for expression of insulin genes
and B cell proliferation markers [92].
In mice lacking the OC, decreased B cells prolifera-
tion, insulin resistance, and abnormal levels of visceral
fat is reported [91]. In male mice, OC increases the tes-
tosterone levels. It has been hypothesized that the effects
of OC on metabolism is mediated through testosterone
as well [76]. The last but not the list, The OC levels have
positive correlation with adiponectin and it is likely that
combination of these two proteins produces some posi-
tive effects on insulin sensitivity [93].
In accordance to animal studies, serum levels of OC
and/or undercarboxylated osteocalcin (ucOC) are shown
to be decreased in patients with diabetes (T1DM and
T2DM) [94, 95]. Furthermore, it seems there is an inverse
association between serum levels of OC and HbA1c; along
with better control of diabetes, serum levels of OC in-
crease [95]. Although, some studies are done which do
not confirm this association.[96, 97]. Despite the fact that
taking alendronate would cause decrease in the OC and
ucOC levels, two recently published cohort studies have
shown that alendronate might reduce the risk of develop-
ing Type 2 diabetes [96, 97]. One explanation for this
paradox could be the not exactly identified role of ucOC
in human glucose metabolism [98].
6. Inflammation
There is evidence point to the role of inflammation in
development of diabetes. It is included chronic systemic
inflammation as well as bone inflammation. In animal
models, it has been shown that chronic inflammation
can result in osteoporosis [99]. In clinical studies, an
association between osteoporosis and inflammatory
bowel syndrome is reported [99]. On the other hand,
activation of immune system has a role in both types
of diabetes although its role is more prominent in T1
DM [100, 101]. We have the autoimmune destruction
of B cell in T1DM, while the inflammatory processes
in T2DM are more chronic low-grade inflammatory
process [100, 101].
Bone inflammation is one of the factors by which on-
set of type 1 diabetes is marked, identifying the role of
pro-inflammatory cytokines present at the early stages of
diabetes onset will provide an essential information
about the cause of diabetic bone loss as well as new po-
tential protective treatment [102]. Evidence supporting
this hypothesis is as follows: experimental studies per-
formed on T1DM mice showed that in early days follow-
ing diabetes induction, local and systemic inflammatory
cytokines are increased [59, 103],Simultaneously with
this process, the markers of osteoblast inhibition as well
as adipocytes markers are increased [102, 103].
7. Vasculopathy
Microangiopathy is another mechanism that is thought
to result in bone loss in diabetes [104]. In brain of
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diabetic mice, decrease in brain perfusion as well as
three times attenuation of cumulative vascular density is
noted compared to control group [105]. In 1981, a re-
search performed on 118 diabetic subjects revealed that
in 82 % of iliac crest biopsy, patients showed diabetic
microangiopathy, prominent osteopenia and decreased
sinusoidal capillaries [106]. Although this research could
not be repeated because of ethical issues, later findings
strengthened the hypothesis that diabetic microangiopa-
thy is one of the causes of diabetic osteopenia. In 1983,
Demmler et al also showed there was a decline in dens-
ity of arterial capillaries in the osteoporotic bone [107].
It has been shown that macrovascular and micro-
vascular diabetic complications can be indirectly
linked to increased fragility fracture risk, considering
fall frequency as a confounder [104]. In a study done
by Burkhardt and colleagues, no significant associ-
ation was found between diabetic angiopathy and
BMD, however in T1DM women with coronary heart
disease (CHD) a trend for lower femoral neck BMD
than those without CHD was reported. These findings
support the above hypothesis [108].
8. Anti-diabetic agents
Insulin has some anabolic effects on bone [109]. On
the other hand, in patients inject insulin the occurrence
of hypoglycemia increases the fall-related fractures, there
is a direct association between daily insulin need and
low BMD. This might be due to the fact that higher daily
insulin requirement is an indicative of disease progres-
sion and complications [110].
Oral anti-diabetic agents produce various and some-
times opposite effects on bone metabolism.
8.1. Agents with positive effects on bone metabolism
8.1.1. Metformin and sulfonylurea have protective
effects on bone fractures [111]. Both agents
showed osteogenic effect in in-vitro studies
that is mediated through increased prolifera-
tion and differentiation toward osteoblasts
[111].
8.1.2. Dipeptidyl peptidase-4 (DPP-4) inhibitors such
as sitagliptin has anabolic effects on bone [112].
8.2. Agents with negative effects on bone metabolism
TZDs including pioglitazone and rosiglitazone de-
crease the differentiation of bone marrow cell toward
osteoblast and increase the adipocyte differentiation
[113]. A meta-analysis showed that consumption of this
group of anti-hyperglycemic agents is associated with in-
creased risk of fracture specially in women [56] . More
recently it was suggested that some clinical trials should
be performed in order to assess the effects of PTH
therapy in prevention of fracture in patients consuming
these agents [56].
It should be noted that long term effects of anti-
diabetic medications on bone metabolism are missing
and to have a broad and accurate conclusion such stud-
ies are required.
Conclusions
There is a lot of evidence that demonstrate both types of
diabetes have a negative effect on bone strength and
both types are associated with an increased risk of frac-
ture [4, 5, 108]. We might suggest that among mecha-
nisms explored in this paper, the hyperglycemia and
AGEs have more prominent role [9]. However, studies
that focus on other mechanisms by which diabetes affect
the fragility of bones are highly recommended. In this
way we are more likely to find practical therapeutic
approaches for proper and timely management of
osteoporosis.
Evaluation of effects of diabetic complications such as
micro- and macro-angiopathy, nephropathy and neur-
opathy on bone health can also be helpful. Bone itself
can affect the glucose metabolism and diabetes risk [91,
95]; however, the underlying mechanism by which the
bone affects the metabolism of the body is still elusive.
In this regard, another point is to stress on conducting
studies related to bone-derived hormones. All debates
that we mentioned above can express a new interesting
concept. Based on this concept, bone is not a simple
organ that only gets influence from other organs, but it
is an endocrine organ that by secreting the agents such
as osteocalcin, adiponectin, and visfatin can affect the
body metabolism.
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